Aim: We performed longitudinal evaluations of the neurocognitive status in glioma patients to describe possible variations over the course of illness. Materials and methods: Glioma patients underwent a complete battery of standardized neuropsychological tests pre-radiotherapy at 6, 12 and 24 months. Results: We enrolled 130 patients, 67.7% of whom had a deficit in at least one cognitive domain. The most affected domains included executive function (n = 68, 52.3%), long-Term memory (n = 46, 35.3%) and short-Term memory (n = 39, 30%). At follow-up, cognitive status worsened in 31.5%, remained unchanged in 38.4% and improved in 30.1% of patients. Conclusion: This is one of few studies investigating longitudinal neurocognitive status in a wide sample of patients to monitor neuropsychological changes due to tumor progression and treatment administration.
Multidomain and long-Term cognitive evaluation in malignant glioma patients / Tanzilli, A.; Pace, A.; Prosperini, L.; Oppido, P. A.; Telera, S.; Rasile, F.; Farneti, A.; Marucci, L.; Villani, V.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 18:15(2022), pp. 1839-1848. [10.2217/fon-2021-0963]
Multidomain and long-Term cognitive evaluation in malignant glioma patients
Tanzilli A.;Pace A.;Prosperini L.;Oppido P. A.;Villani V.
2022
Abstract
Aim: We performed longitudinal evaluations of the neurocognitive status in glioma patients to describe possible variations over the course of illness. Materials and methods: Glioma patients underwent a complete battery of standardized neuropsychological tests pre-radiotherapy at 6, 12 and 24 months. Results: We enrolled 130 patients, 67.7% of whom had a deficit in at least one cognitive domain. The most affected domains included executive function (n = 68, 52.3%), long-Term memory (n = 46, 35.3%) and short-Term memory (n = 39, 30%). At follow-up, cognitive status worsened in 31.5%, remained unchanged in 38.4% and improved in 30.1% of patients. Conclusion: This is one of few studies investigating longitudinal neurocognitive status in a wide sample of patients to monitor neuropsychological changes due to tumor progression and treatment administration.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


